Boston Scientific Receives Exclusive Expanded Indication for its CRT-Ds

FDA Approval is Based on Results From the Company's Landmark MADIT-CRT Trial

NATICK, Massachusetts, September 20, 2010 - Boston Scientific Corporation (NYSE: BSX) today announced that
the U.S. Food and Drug Administration (FDA) has approved an expanded
indication for its cardiac resynchronization therapy defibrillators (CRT-Ds),
including the COGNIS(R) CRT-D. The exclusive expanded indication is effective
immediately and makes Boston Scientific CRT-Ds the only devices approved by
the FDA for patients in all New York Heart Association (NYHA) classes of
heart failure[1].

The Company's CRT-Ds had previously been approved for NYHA
Class III and IV patients. The expanded indication approves Boston Scientific
CRT-Ds for use in high risk[2] NYHA Class I and II patients with Left Bundle
Branch Block[3] (LBBB). These patients accounted for 70 percent of the
MADIT-CRT clinical trial population.

"The MADIT-CRT trial demonstrated that Boston Scientific's
CRT-Ds reduce death and heart failure events, even for patients without
symptoms," said Kenneth Stein, M.D., Senior Vice President and Chief Medical
Officer, CRM, for Boston Scientific's Cardiology, Rhythm and Vascular Group.
"Preventing or delaying a first heart failure event in NYHA Class I and II
patients with LBBB is critical because these patients are eight times more
likely to have a recurring event after their initial event."

In response to a request from the FDA, Boston Scientific
worked with the MADIT-CRT Executive Committee to perform further analysis of
the trial data to determine if there were additional criteria to identify
patients at risk for heart failure. The Company's analysis showed that LBBB
was the best baseline characteristic to differentiate which Class I and II
patients would be most likely to benefit from a CRT-D. MADIT-CRT data
demonstrated that patients with LBBB who received CRT-D therapy showed a
relative risk reduction of all-cause mortality or first heart failure event
of 57 percent when compared to those who received implantable cardioverter
defibrillator therapy (p<0.001).

"We are extremely pleased with the FDA's decision to expand
the indication for Boston Scientific CRT-Ds, which substantially broadens the
population of heart failure patients who can benefit from this therapy," said
Hank Kucheman, Executive Vice President and Group President, Cardiology,
Rhythm and Vascular for Boston Scientific. "The addition of LBBB to the
indication provides a strong, objective identifier of patients eligible for a
CRT-D, meeting the needs of both implanting and referring physicians."

MADIT-CRT is the world's largest randomized CRT-D study of
NYHA Class I and II patients, with more than 1,800 patients enrolled at 110
centers worldwide.

Boston Scientific is a worldwide developer, manufacturer and
marketer of medical devices whose products are used in a broad range of
interventional medical specialties. For more information, please visit:
www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934. Forward-looking statements may be
identified by words like "anticipate," "expect," "project," "believe,"
"plan," "estimate," "intend" and similar words. These forward-looking
statements are based on our beliefs, assumptions and estimates using
information available to us at the time and are not intended to be guarantees
of future events or performance. These forward-looking statements include,
among other things, statements regarding our product performance, clinical
outcomes, regulatory approval of our products, and our growth strategy. If
our underlying assumptions turn out to be incorrect, or if certain risks or
uncertainties materialize, actual results could vary materially from the
expectations and projections expressed or implied by our forward-looking
statements. These factors, in some cases, have affected and in the future
(together with other factors) could affect our ability to implement our
business strategy and may cause actual results to differ materially from
those contemplated by the statements expressed in this press release. As a
result, readers are cautioned not to place undue reliance on any of our
forward-looking statements.

Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends; intellectual
property; litigation; financial market conditions; and future business
decisions made by us and our competitors. All of these factors are difficult
or impossible to predict accurately and many of them are beyond our control.
For a further list and description of these and other important risks and
uncertainties that may affect our future operations, see Part I, Item 1A -
Risk Factors in our most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission, which we may update in Part II, Item 1A -
Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file
thereafter. We disclaim any intention or obligation to publicly update or
revise any forward-looking statements to reflect any change in our
expectations or in events, conditions, or circumstances on which those
expectations may be based, or that may affect the likelihood that actual
results will differ from those contained in the forward-looking statements.
This cautionary statement is applicable to all forward-looking statements
contained in this document.

    ---------------------------------

    [1] The NYHA clinical classifications of heart failure rank patients as
        Class I-II-III-IV, according to the degree of symptoms or functional
        limits, from asymptomatic to bed ridden.

    [2] High-risk is defined as QRS width (greater than or equal to) 130
        milliseconds and Left Ventricular Ejection Fraction (greater than or
        equal to) 30 percent. MADIT-CRT patients are asymptomatic or mildly
        symptomatic, NYHA Class I (ischemic) and Class II (ischemic and
        non-ischemic).

    [3]LBBB is a condition in which the activation of the left ventricle is
       delayed. As a result, portions of the left ventricle contract later
       than the rest of the left ventricle and right ventricle, reducing the
       heart's pumping ability. The intent of cardiac resynchronization
       therapy is  to restore synchronous contraction of the ventricles.

    CONTACT:
    Géraldine Varoqui
    Boston Scientific
    Public Relations International
    +49-170-782-85-58
    varoquig@bsci.com

CONTACT: Géraldine Varoqui, Boston Scientific, Public Relations International, +49-170-782-85-58, varoquig at bsci.com .